Kenvue Inc.
Kenvue Inc. Completes $750 Million Senior Notes Offering
Summary
On May 22, 2025, Kenvue Inc. finalized the issuance of $750 million aggregate principal amount of 4.850% Senior Notes due 2032. The Notes were issued under an indenture between Kenvue and Deutsche Bank Trust Company Americas as trustee, with the proceeds intended for general corporate purposes. The Notes bear interest at a rate of 4.850% per annum, payable semi-annually, and mature on May 22, 2032. The offering includes provisions limiting certain corporate actions by Kenvue and its subsidiaries. A copy of the Second Supplemental Indenture is attached as Exhibit 4.1.
Profitelligence Alerts
Get alerts for KVUE
Be first to know when Kenvue Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Kenvue Inc.
Kenvue Inc. is a consumer healthcare and pharmaceutical company. It focuses on delivering a range of health-centric products, spanning hygiene, pain relief, and other wellness categories. With deep-rooted expertise in pharmaceuticals, Kenvue Inc. targets the health and wellness needs of individuals, providing both prescription and over-the-counter solutions. The company has established itself as a vital entity in the consumer health sector, significantly impacting community health standards and individual lives. Positioned in the pharmaceutical industry, Kenvue Inc. collaborates with healthcare providers to enhance its product reach and efficacy. Its broad portfolio includes well-known brands and formulations that are trusted globally by consumers seeking reliable health solutions. As a player in this sector, Kenvue Inc. contributes to the enhancement of public health, highlighting its prominence in both domestic and international markets.
Official SEC Documents
Advertisement